40.5% Quit Smoking After Psilocybin Therapy, Versus 10% With Nicotine Patches

Health Science Hub Editorial

Evidence review & editorial synthesis

In a randomized clinical trial, 40.5% of smokers receiving psilocybin-assisted therapy achieved prolonged abstinence six months after their quit date. Among those assigned nicotine patches with the same behavioral therapy program, the figure was 10.0%. That is a 30.5-percentage-point gap and roughly four times the quit rate, one of the most striking results in recent smoking-cessation research.

The finding comes from a 2026 Johns Hopkins pilot trial published in JAMA Network Open, not from the November editorial that brought renewed attention to psychedelic treatments for addiction.

Four in ten versus one in ten

The trial randomly assigned 82 adult smokers to two approaches. Forty-two received one supervised high-dose psilocybin session; 40 started an established eight- to ten-week nicotine-patch regimen. Importantly, both groups also received a structured, 13-week cognitive behavioral therapy program designed to help people stop smoking.

Six months later, 17 of the 42 participants assigned psilocybin (40.5%) met the primary endpoint of biochemically verified prolonged abstinence, compared with four of 40 (10.0%) assigned nicotine patches. The between-group difference was statistically significant (p = 0.003). Looking at another endpoint, verified abstinence during the previous seven days, researchers found rates of 52.4% versus 25.0%.

In other words, the result was not merely that people reported smoking less. Researchers checked evidence of abstinence, and the separation persisted to the six-month assessment.

Why a single session is such an unusual approach

Nicotine replacement aims to soften withdrawal and cravings while someone builds a life without cigarettes. Psilocybin-assisted therapy takes a very different route: a supervised psychedelic experience is embedded in psychological preparation and behavior-change work. Researchers are investigating whether it can help disrupt entrenched patterns and change how people relate to the urge to smoke.

People in the trial were screened for psychiatric health, and researchers tracked their outcomes for months after the quit date. The clinical setting matters because psychedelic experiences can be unusually intense and require careful screening and professional support. The treatment studied was not a pill taken at home or a psychedelic substituted for counseling. It was one clinically supervised session plus weeks of behavioral treatment. The result raises an intriguing question: could some smokers benefit from a treatment that changes the psychological grip of the habit, rather than primarily supplying nicotine during withdrawal?

An earlier small, uncontrolled pilot from the same research program reported substantial abstinence many months after treatment. The new randomized comparison is more informative because it tests psilocybin against an active treatment rather than simply tracking a single group over time.

What can improve quit rates today?

The psilocybin findings are compelling, but proven options already exist. A major Cochrane review found that combining a steady-release nicotine patch with a faster-acting form of nicotine replacement increased the likelihood of long-term smoking cessation by about 27% relative to using one form alone. The faster-acting option is used when cravings break through, while the patch provides background coverage.

For someone exploring this approach, nicotine replacement gum or lozenges are practical options to discuss with a pharmacist, particularly alongside a patch and structured behavioral support. Product strength and dosing should match smoking patterns and the product instructions. This combination was not the control treatment in the psilocybin trial, so the 40.5% versus 10.0% comparison does not establish superiority over optimized combination nicotine replacement.

Other well-supported approaches include prescription varenicline or cytisine where available, together with behavioral counseling. A Cochrane network review found these medications, and combination nicotine replacement, among the most effective established approaches. Choosing a supported treatment plan, rather than relying on willpower alone, changes the odds. For someone whose previous attempt with a patch did not succeed, the distinction between a patch by itself and a patch plus fast-acting replacement is especially relevant. This is a way to improve established care without waiting for experimental treatments.

A promising new route, not a do-it-yourself treatment

This was an 82-person pilot trial in psychiatrically healthy, highly motivated volunteers. Participants and researchers knew which treatment was given, and the patch-only comparison did not test every best-practice quit strategy. Psilocybin can cause intense psychological effects and is not an approved routine smoking-cessation treatment; the study does not establish that unsupervised use is safe or effective.

Still, the result deserves attention. A single supervised psilocybin session paired with behavioral therapy produced a substantially higher six-month abstinence rate than a nicotine-patch program paired with the same therapy. The most important next question is whether this difference holds up in larger, rigorously controlled trials against optimized smoking-cessation care.

Scientific References & Further Reading


Disclaimer: This article is for informational purposes only and does not constitute medical advice. It is not a substitute for diagnosis, treatment, or individualized medical care.

As an Amazon Associate, Health Science Hub earns from qualifying purchases.